BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 24928469)

  • 61. A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients.
    Wang C; Ding M; Xia M; Chen S; Van Le A; Soto-Gil R; Shen Y; Wang N; Wang J; Gu W; Wang X; Zhang Y; Zen K; Chen X; Zhang C; Zhang CY
    EBioMedicine; 2015 Oct; 2(10):1377-85. PubMed ID: 26629532
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Down-regulation of microRNA-124 is correlated with tumor metastasis and poor prognosis in patients with lung cancer.
    Zhang Y; Li H; Han J; Zhang Y
    Int J Clin Exp Pathol; 2015; 8(2):1967-72. PubMed ID: 25973090
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
    Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Validation for histology-driven diagnosis in non-small cell lung cancer using hsa-miR-205 and hsa-miR-21 expression by two different normalization strategies.
    Charkiewicz R; Pilz L; Sulewska A; Kozlowski M; Niklinska W; Moniuszko M; Reszec J; Manegold C; Niklinski J
    Int J Cancer; 2016 Feb; 138(3):689-97. PubMed ID: 26311306
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Circulating microRNAs as biomarkers of adult Crohn's disease.
    Jensen MD; Andersen RF; Christensen H; Nathan T; Kjeldsen J; Madsen JS
    Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1038-44. PubMed ID: 26230660
    [TBL] [Abstract][Full Text] [Related]  

  • 66. microRNA-137 functions as a tumor suppressor in human non-small cell lung cancer by targeting SLC22A18.
    Zhang B; Liu T; Wu T; Wang Z; Rao Z; Gao J
    Int J Biol Macromol; 2015 Mar; 74():111-8. PubMed ID: 25498886
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
    Liu L; Qu W; Zhong Z
    Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Ulivi P; Canale M; Passardi A; Marisi G; Valgiusti M; Frassineti GL; Calistri D; Amadori D; Scarpi E
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361687
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
    Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
    Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
    PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
    Botta C; Barbieri V; Ciliberto D; Rossi A; Rocco D; Addeo R; Staropoli N; Pastina P; Marvaso G; Martellucci I; Guglielmo A; Pirtoli L; Sperlongano P; Gridelli C; Caraglia M; Tassone P; Tagliaferri P; Correale P
    Cancer Biol Ther; 2013 Jun; 14(6):469-75. PubMed ID: 23760488
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients.
    Mavridis K; Gueugnon F; Petit-Courty A; Courty Y; Barascu A; Guyetant S; Scorilas A
    Br J Cancer; 2015 Apr; 112(9):1527-35. PubMed ID: 25867273
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling.
    Fassina A; Cappellesso R; Fassan M
    Chest; 2011 Nov; 140(5):1305-1311. PubMed ID: 21622546
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic Value of Expression of MicroRNAs in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhan B; Lu D; Luo P; Wang B
    Clin Lab; 2016 Nov; 62(11):2203-2211. PubMed ID: 28164670
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
    Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
    Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
    Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab.
    Halvorsen AR; Sandhu V; Sprauten M; Flote VG; Kure EH; Brustugun OT; Helland Å
    Acta Oncol; 2018 Sep; 57(9):1225-1231. PubMed ID: 29683761
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
    Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
    Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.